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Numerous studies have shown that infil-
tration of lymphocytes into tumor tissue is as-
sociated with better prognosis (Bindea et al., 
2013; Lohr et al., 2013; Schmidt et al., 2018; 
Heimes et al., 2017a, b). This prognostic in-
fluence has been seen in many tumor types, 
including colon (Schmidt et al., 2012), breast 
(Lohr et al., 2013; Schmidt et al., 2008; Go-
doy et al., 2014) and lung (Botling et al., 
2013; Grinberg et al., 2017; Jabs et al., 2017). 
With the introduction of programmed death 
ligand 1 (PD-L1) targeting therapy, immune-
inhibitory mechanisms have become a major 
field of research (Garon et al., 2015; Rizvi et 
al., 2015a, b; Herbst et al., 2016; Pardoll, 
2012; Creelan, 2014; Aguiar et al., 2017). 
However, the prognostic role of PD-L1 in 
non-small cell lung cancer (NSCLC) in pa-
tients not treated with PD-1 targeting thera-
pies still is unclear. To gain a better under-
standing, a study recently published in the 
Journal of Thoracic Oncology immunohisto-
chemically analyzed tissue microarrays of 
705 patients with NSCLC and additionally 
considered publicly available transcriptomics 
data of 1724 patients (Edlund et al., 2019). 
Key findings of this study in patients without 
PD-1 targeting therapies are: (1) Infiltration 
of T-, B- and plasma cells is associated with 
better prognosis, similar to previous studies; 
(2) This association is strongest in highly pro-
liferative tumors; (3) PD-L1 is not associated 
with prognosis in the total cohort of NSCLC 
patients; (4) However, a significant associa-
tion of PD-L1 positivity with shorter survival 
was obtained in the never-smokers. This asso-
ciation was validated in independent patients 
on the RNA level. 
This result is of relevance, because it 
shows that immune modifiers have different 
roles in NSCLC of smokers and non-smokers. 
It will be important to consider this difference 
in therapy studies targeting the PD-1/PD-L1 
axis. Predicting prognosis and response to 
therapy remains a challenging task (Hellwig 
et al., 2016; Lohr et al., 2015; Weisner et al., 
2019) with many modifying factors, e.g. pro-
liferation (Siggelkow et al., 2012), antioxida-
tive status (Cadenas et al., 2010, 2014, 2019) 
and metabolism (Marchan et al., 2017; Stew-
art et al., 2012) playing an important role. The 
present study of Edlund and colleagues helps 
to gain an overview which key factors modify 
the prognostic role of tumor infiltrating lym-
phocytes.  
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